How exciting! Dapagliflozin (Farxiga) initially approved for treatment of type 2 diabetes now has an indication beyond its use in diabetes. FDA has given dapagliflozin an indication for heart failure with reduced ejection fraction (HFrEF) to reduce risk of cardiovascular death and hospitalization for heart failure. Please click below to read more details.
https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-type-heart-failure
Please share your thoughts and subscribe to receive my blogs.
#heart #failure #indication #Farxiga #FDA
Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram.